12:00 AM
 | 
Dec 14, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

DiabeCell: Interim Phase I/IIa data

Interim data from an open-label, dose-escalation, New Zealand Phase I/IIa trial showed that the daily insulin dose for 1 patient receiving the DiabeCell implant had started to drop...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >